Vir Biotechnology (VIR) announced that the first patient has been dosed in the company’s Phase 1 clinical trial evaluating VIR-5525, an investigational dual-masked T-cell engager targeting EGFR. VIR-5525 will be evaluated for the treatment of a variety of EGFR-expressing solid tumors in areas of high unmet need such as non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Insider Moves: Fastenal, Vir, Cipher, Verisign, HEICO
- CoreWeave initiated, Texas Instruments upgraded: Wall Street’s top analyst calls
- Vir Biotechnology initiated with an Outperform at Raymond James
- Positive Outlook on Vir Biotechnology’s VIR-5500 Amid Competitive mCRPC Market
- Vir Biotechnology Holds 2025 Annual Stockholder Meeting